

Financial news for VSAR dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for VSAR dated on 2018-10-10: Stocks Which Set New 52-Week Low Yesterday, October 9th

Financial news for VSAR dated on 2018-09-24: Stocks Which Set New 52-Week Low Friday, September 21st

Financial news for VSAR dated on 2018-08-07: Versartis Q2 EPS \$(0.27) Beats \$(0.96) Estimate

Financial news for VSAR dated on 2018-07-10: Versartis Form 425 Shows Co. Has Completed Phase 1 Study Of AVB-S6-500 Met Safety And Tolerably Endpoints For Trial; Shares Up 17.5% After Hours

Financial news for VSAR dated on 2018-06-11: 21 Stocks Moving In Monday's Pre-Market Session

Financial news for VSAR dated on 2018-06-04: Benzinga Pro's Top 10 Most-Searched Tickers For The Evening Of Mon., Jun. 4

Financial news for VSAR dated on 2018-06-04: Versartis Enters into Merger Agreement with Aravive Biologics In All-Stock Transaction, Each Co. Is Expected To Own ~50% Of The Combined Company

Financial news for VSAR dated on 2018-05-08: Versartis Q1 EPS \$(0.25) Does Not Compare To \$(0.86) Estimate

Financial news for VSAR dated on 2018-03-02: Versartis Shares Up 12.9% Premarket After Co. Late Thursday Reported Q4 EPS \$0.87 vs \$(1.00) Est.

Financial news for VSAR dated on 2018-03-02: Canaccord Genuity Downgrades Versartis to Hold

Financial news for VSAR dated on 2018-03-01: Versartis Reports Q4 EPS \$0.87 vs \$(0.64) In Prior Year Period, Sales \$40K

Financial news for VSAR dated on 2017-12-07: 42 Biggest Movers From Yesterday

Financial news for VSAR dated on 2017-12-06: 30 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VSAR dated on 2017-12-06: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VSAR dated on 2017-10-30: 50 Biggest Movers From Friday

Financial news for VSAR dated on 2017-10-27: 45 Stocks Moving In Friday's Mid-Day Session

Financial news for VSAR dated on 2017-10-27: 32 Stocks Moving In Friday's Pre-Market Session

Financial news for VSAR dated on 2017-10-26: Versartis to Explore Strategic Transactions, Retains Cowen

Financial news for VSAR dated on 2017-10-26: Versartis Reports Q3 EPS \$(1.40) vs. \$(0.71) Est.

Financial news for VSAR dated on 2017-10-25: 31 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VSAR dated on 2017-10-06: Life (Science) Lessons: The Hows And Whos To Play Biotech

Financial news for VSAR dated on 2017-10-03: 18 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VSAR dated on 2017-09-27: 20 Biggest Mid-Day Losers For Wednesday

Financial news for VSAR dated on 2017-09-27: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VSAR dated on 2017-09-25: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for VSAR dated on 2017-09-22: 12 Biggest Mid-Day Losers For Friday

Financial news for VSAR dated on 2017-09-22: 5 Biggest Price Target Changes For Friday

Financial news for VSAR dated on 2017-09-22: Mid-Day Market Update: Revolution Lighting Technologies Drops Following Reduced FY2017 Outlook; Ascendis Pharma Shares Surge

Financial news for VSAR dated on 2017-09-22: What Do Versartis' Troubles Mean For Opko Health?

Financial news for VSAR dated on 2017-09-22: Mid-Morning Market Update: Markets Edge Lower; CarMax Tops Q2 Expectations

Financial news for VSAR dated on 2017-09-22: Benzinga's Top Upgrades, Downgrades For September 22, 2017

Financial news for VSAR dated on 2017-09-22: Versartis' Somavaratan Still Has A Path Forward; Cantor Reiterates Buy

Financial news for VSAR dated on 2017-09-22: The Market In 5 Minutes

Financial news for VSAR dated on 2017-09-22: PiperJaffray Downgrades Versartis to Neutral

Financial news for VSAR dated on 2017-09-22: 19 Stocks Moving In Friday's Pre-Market Session

Financial news for VSAR dated on 2017-09-22: Cantor Fitzgerald Defends Versartis With Shares Down 80+%; Maintains Overweight Rating, Lowered Price Target From \$34 To \$14

Financial news for VSAR dated on 2017-09-22: SunTrust Robinson Humphrey Downgrades Versartis to Hold

Financial news for VSAR dated on 2017-09-22: Cowen & Co. Downgrades Versartis to Market Perform

Financial news for VSAR dated on 2017-09-22: Barclays Downgrades Versartis to Underweight

Financial news for VSAR dated on 2017-09-21: Versartis Shares Resume Trade, Now Down 82%

Financial news for VSAR dated on 2017-09-21: Versartis Shares To Resume Trade At 5 p.m. EDT

Financial news for VSAR dated on 2017-09-21: Versartis Shares Halted, News Pending

Financial news for VSAR dated on 2017-09-08: Companies Holding Shareholder Meetings Today Include Capital Product Partners, Retractable Technologies, RF Industries, Safe Bulkers, Sonoma Pharmaceuticals, Versartis, and VolitionRX

Financial news for VSAR dated on 2017-08-25: From A(erie) To Z(ynherba): Biotech Catalysts Lined Up For Second Half Of 2017

Financial news for VSAR dated on 2017-08-23: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for VSAR dated on 2017-07-27: Versartis Reports Q2 EPS \$(1.04) vs \$(0.84) Est.

Financial news for VSAR dated on 2017-05-05: Benzinga's Top Upgrades, Downgrades For May 5, 2017

Financial news for VSAR dated on 2017-05-05: Cantor Fitzgerald Initiates Coverage On Versartis with Overweight Rating, Announces \$34.00 Price Target

Financial news for VSAR dated on 2017-04-27: VERSARTIS Q1 EPS \$(0.85) vs \$(0.72) Est, No Sales

Financial news for VSAR dated on 2017-04-03: Versartis Issues Second Release on Somavaratan Data, Says 3-Year Data Showed Safety, Efficacy in Line with Historical US Daily rhGH Data in Pediatric GHD

Financial news for VSAR dated on 2017-04-03: Versartis Reports New Data on Long-Acting Somavaratan in GHD: Says 'Baseline characteristics of Phase 3 VELOCITY trial population balanced between study arms and comparable to Phase 2'

Financial news for VSAR dated on 2017-03-29: Versartis, Inc. Director AKKARAJU SRINIVAS Buys 571,429 Shares @ Avg Price: \$12.25 (Form4)

Financial news for VSAR dated on 2017-03-15: Versartis Names Tracy Woody as Chief Commercial Officer

Financial news for VSAR dated on 2017-03-09: Benzinga's Top Upgrades, Downgrades For March 9, 2017

Financial news for VSAR dated on 2017-03-09: Barclays Sees 40% Upside In Versartis Over Next Year

Financial news for VSAR dated on 2017-03-09: Barclays Initiates Coverage On Versartis With Overweight, Announces \$28 Price Target

Financial news for VSAR dated on 2017-02-21: Versartis Reports Q4 EPS \$(0.64) vs \$(0.62) Est.

Financial news for VSAR dated on 2017-01-31: Versartis Promotes Joshua T. Brumm to COO and Paul Westberg to Chief Business Officer

Financial news for VSAR dated on 2017-01-04: Form 4 Filing from Perceptive Advisors on Versartis Shows Purchase of 94,750 Shares at \$14.658

Financial news for VSAR dated on 2016-12-20: 8 Biggest Price Target Changes For Tuesday

Financial news for VSAR dated on 2016-12-20: Credit Suisse Upgrades Versartis to Outperform, Raises Target to \$20.00

Financial news for VSAR dated on 2016-12-01: SunTrust Robinson Humphrey Initiates Coverage On Versartis at Buy, Announces \$25.00 Target

Financial news for VSAR dated on 2016-11-03: Versartis Reports Q3 EPS \$(0.92) vs. Est. \$(0.26)

Financial news for VSAR dated on 2016-10-17: Versartis Phase 3 Enrollment Granted Approval In Japan

Financial news for VSAR dated on 2016-10-04: Dir Akkaraju Buys 571,429 Shares of Versartis @\$12.25/Share -Form 4

Financial news for VSAR dated on 2016-10-04: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VSAR dated on 2016-10-04: PiperJaffray Initiates Coverage on Versartis at Overweight

Financial news for VSAR dated on 2016-09-28: Stock Offerings En Vogue Over Last Several Sessions

Financial news for VSAR dated on 2016-09-28: 12 Biggest Mid-Day Losers For Wednesday

Financial news for VSAR dated on 2016-09-28: Versartis Reports Pricing of 4.898M Shares at \$12.25/Share

Financial news for VSAR dated on 2016-09-28: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VSAR dated on 2016-09-27: Versartis Reports Offering of Common Shares

Financial news for VSAR dated on 2016-09-26: Versartis Initiates Phase 3 Trial for Somavaratan in Japan

Financial news for VSAR dated on 2016-09-12: Versartis Reports Data from Up to 30 Mos. of Somavaratan Treatment for Pediatric Growth Hormone Deficiency

Financial news for VSAR dated on 2016-09-01: Amunix Announces that Versartis has Completed Enrollment of Phase 3 Study of Somavaratan in Pediatric Patients with Growth Hormone Deficiency

Financial news for VSAR dated on 2016-08-09: After-Hours Gainers Aug. 9, 2016: CLNE Up 18.5%, OCN 12%, VSAR 11.5%, YELP 10.3%, DXPE 8.9%, BBSI 8.6%, SPHS 7.4%, DHT 7.7%, EKSO 7.6%, CDXS 7.5%, YRD 7.4%, VRNS 7.3%

Financial news for VSAR dated on 2016-08-09: Teijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan

Financial news for VSAR dated on 2016-08-09: Versartis Shares to Resume Trade at 4:35 p.m. EDT

Financial news for VSAR dated on 2016-08-09: Versartis Shares Halted to Announce: Strategic Alliance with Teijin for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan; Versartis Will Receive \$40M Upfront Payment, Could Receive Added \$125M

Financial news for VSAR dated on 2016-07-28: Versartis Reports Q2 EPS \$(0.75) vs. Est. \$(0.84)

Financial news for VSAR dated on 2016-04-28: Versartis Reports Q1 EPS \$(0.82) vs. Est. \$(0.76)

Financial news for VSAR dated on 2016-04-07: Northland Securities Initiates Coverage on Versartis at Outperform

Financial news for VSAR dated on 2016-04-04: Versartis Offers Confirmatory Year Two Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Meeting

Financial news for VSAR dated on 2016-03-30: Versartis Names Colin Hislop, M.D., as Chief Medical Officer

Financial news for VSAR dated on 2016-03-29: More Mid-Cap Biotech M&A May Be Coming

Financial news for VSAR dated on 2016-03-14: Versartis Announces Two Abstracts from Ongoing Pediatric Extension Study of Somavaratan Selected for Late-Breaker Presentations at the Endocrine Society's 98th Annual Meeting

Financial news for VSAR dated on 2016-02-26: Advent Life Sciences LLP Reports 7.7% Passive Stake in Versartis in 13G

Financial news for VSAR dated on 2016-02-23: Empire Asset Management Terminates undefined Rating on Versartis

Financial news for VSAR dated on 2016-02-18: Versartis Reports Q4 EPS \$(0.69) vs \$(0.71) Est.

Financial news for VSAR dated on 2015-12-17: UPDATE: Credit Suisse on Versartis Downgrade: 'Lack of Significant Catalysts in 2016 Makes VSAR Less Attractive

Financial news for VSAR dated on 2015-12-17: Credit Suisse Downgrades Versartis to Underperform, Lowers PT to \$12.00

Financial news for VSAR dated on 2015-12-04: Versratis Files for Up to \$200M Mixed Shelf

Financial news for VSAR dated on 2015-10-29: Versatis Reports Q3 EPS \$(0.69) vs. Est. \$(0.71)

Financial news for VSAR dated on 2015-10-01: Versartis Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study at Late-Breaker Session at ESPE Annual Meeting

Financial news for VSAR dated on 2015-09-18: Benzinga's Volume Movers

Financial news for VSAR dated on 2015-09-18: Versartis Reports Confirmatory 18-Month Data From Ongoing Extension Study of Somavaratan in GHD Children

Financial news for VSAR dated on 2015-09-10: Versartis Starts Phase 2 Trial of Monthly Somavaratan in Adults With Growth Hormone Deficiency

Financial news for VSAR dated on 2015-08-20: Stocks Hitting 52-Week Lows

Financial news for VSAR dated on 2015-08-20: Benzinga's Top Initiations

Financial news for VSAR dated on 2015-08-20: Credit Suisse Initiates Coverage on Versartis at Neutral, Announces \$20.00 PT

Financial news for VSAR dated on 2015-08-19: Credit Suisse Initiates Coverage on Versartis at Neutral, Announces \$20.00 PT

Financial news for VSAR dated on 2015-08-13: Morgan Stanley Initiates Coverage on Versartis at Equal-weight, Announces \$17.00 PT

Financial news for VSAR dated on 2015-08-04: Versartis Reports Q2 EPS \$(0.67) vs. Est. \$(0.64)

Financial news for VSAR dated on 2015-07-06: Mid-Afternoon Market Update: Dow Dips Over 100 Points; Crude Oil Tumbles 5.5%

Financial news for VSAR dated on 2015-07-06: Mid-Day Market Update: Weight Watchers Surges On Takeover Rumors; Horsehead Holding Shares Drop

Financial news for VSAR dated on 2015-07-06: Monday's Mid-Day Movers: Greece Says No, Crude Tumbles

Financial news for VSAR dated on 2015-07-06: Mid-Morning Market Update: Markets Open Lower; Aetna To Acquire Humana For \$230/Share

Financial news for VSAR dated on 2015-07-06: Morning Market Gainers

Financial news for VSAR dated on 2015-07-06: Versartis Reports Removal of FDA Partial Clinical Hold and Continuation of VRS-317 Phase 3 Clinical Trial

Financial news for VSAR dated on 2015-05-06: Versartis Reports Q1 EPS Loss \$0.79 Vs est Loss \$0.63

Financial news for VSAR dated on 2015-04-14: SunTrust Robinson Humphrey Initiates Coverage on Versartis at Buy, Announces \$50.00 PT

Financial news for VSAR dated on 2015-04-13: Versartis Begins Phase 2/3 Trial of VRS-317 in Japan for Children With Growth Hormone Deficiency

Financial news for VSAR dated on 2015-03-06: Versartis Presents 12-Month Data for VRS-317 at Late-Breaker Session at Endocrine Society's Annual Meeting

Financial news for VSAR dated on 2015-02-12: Versartis Reports Q4 Loss of \$0.65/Share

Financial news for VSAR dated on 2015-02-02: Microsoft, Bank Of New York And Others Insiders Have Been Buying

Financial news for VSAR dated on 2015-01-21: Versartis Prices ~4.347M Share Offering @\$17.25/Share

Financial news for VSAR dated on 2015-01-21: 5 Biotech Secondaries Traders Are Watching

Financial news for VSAR dated on 2015-01-20: Versartis Announces Proposed Offering of Common Stock to Raise Gross Proceeds of ~\$75M

Financial news for VSAR dated on 2015-01-08: Versartis Announces Initiation of Phase 3 Study

Financial news for VSAR dated on 2015-01-06: Versartis Files for Up to \$86.3M Common Stock Offering

Financial news for VSAR dated on 2015-01-05: Versartis Reports Positive 12-Mo. Data for VRS-317 from Ongoing Extension Study: Successful Dose Response Further Confirms Phase 3 Trial Design

Financial news for VSAR dated on 2014-12-29: Versartis to Hold Conference Call to Discuss VRS-317 Clinical Update From Ongoing Extension Study

Financial news for VSAR dated on 2014-11-06: Versartis, Inc. Reports Q3 EPS of \$(0.57) vs \$(0.53) Est

Financial news for VSAR dated on 2014-09-10: Events for the Week of Sept. 8-12

Financial news for VSAR dated on 2014-08-05: Versartis Reports Q2 Loss of \$0.36/Share vs \$0.45/Share Loss

Financial news for VSAR dated on 2014-06-23: Versartis Announces presentation of Positive Phase 2a Results for VRS-317

Financial news for VSAR dated on 2014-05-21: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Financial news for VSAR dated on 2014-05-05: Versartis, Inc. Reports Q1 EPS of \$(2.57) Which May Not Compare \$(6.37) Est

Financial news for VSAR dated on 2014-04-15: Mid-Day Market Update: US Stocks Turn Red; Pep Boys Shares Drop After Q4 Results

Financial news for VSAR dated on 2014-04-15: Mid-Morning Market Update: Markets Gain; Johnson & Johnson Profit Beats Street View

Financial news for VSAR dated on 2014-04-15: Morning Market Movers

Financial news for VSAR dated on 2014-04-15: Citigroup Initiates Coverage on

Versartis, Inc. at Buy, Announces \$60.00 PT

Financial news for VSAR dated on 2014-04-15: Morgan Stanley Initiates Coverage on Versartis, Inc. at Overweight, Announces \$79.00 PT

Financial news for VSAR dated on 2014-03-24: Six IPOs Hit Wall Street On March 21, 2014

Financial news for VSAR dated on 2014-03-21: Shares of Versartis Open for Trade at \$28/Share, Priced at \$21